Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling.

Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling.

Mamounas Eleftherios P; Budd G Thomas; Miller Kathy D

Clinical advances in hematology & oncology : H&O

2008

2008-02

Advances in breast cancer research have confirmed that this malignancy is not a single disease, but rather a collection of genetically distinct diseases with different treatment requirements. In recent years, several studies have confirmed the clinical validity of the Oncotype DX breast cancer assay, not only as a way to predict recurrence but also as a tool for determining therapeutic benefit from adjuvant chemotherapy. Recently, Drs. Terry Mamounas, G. Thomas Budd, and Kathy Miller answered questions about the Oncotype DX assay that are particularly relevant to routine clinical practice. This expert dialog provides a useful update and essential clinical insights about how, why, and when community oncologists may want to incorporate this multi-gene assay into their care of breast cancer patients. In addition, sample case studies offer tangible examples of the practical application of Oncotype DX.

Adult; Female; Humans; Middle Aged; Genotype; Clinical Trials as Topic; *Gene Expression Profiling; *Breast Neoplasms/diagnosis/genetics/therapy; Breast Neoplasms/classification/*drug therapy/*genetics/surgery; Gene Expression Profiling/*methods; Polymerase Chain Reaction/methods; Tamoxifen/therapeutic use; Receptors; Antineoplastic Agents; Adjuvant; Chemotherapy; Adjuvant/methods; Estrogen/analysis; Hormonal/therapeutic use

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

1–8

2

6